Home > Publications/Guides > Presentations

Presentations

ADME

Are TripleTOF® systems the future for HT-ADME/toxicity screening?

High Throughput Physical Chemistry Assays - Advances and Application

Transporter DDI - An Evaluation of Approaches and Methodologies

Incosmetics_Skin Metabolism Presentation_April 2017

Methods to evaluate in vitro models of skin metabolism

'Physicochemical Properties and their Relation to ADMET' webinar – PDF VERSION
15th May 2013

The Evolution of in vitro ADME-Tox Screening - A 20 year Perspective

Understanding species and tissue-dependent differences in carboxylesterase-mediated metabolism

Cyprotex 4th European Drug Discovery Workshop 2010: Transporters and cytochrome P450 interplay in defining hepatic drug clearance by Prof Brian Houston (Director of the Centre for Applied Pharmacokinetic Research, University of Manchester)

Cyprotex 4th European Drug Discovery Workshop 2010: Variations in permeability assays and their potential issues by Dr. Kevin Weigl (Senior Scientist, Abbott Products GmbH)

Cyprotex 4th European Drug Discovery Workshop 2010: Insoluble substances in in-vitro assays by Dr. Christa Kneip (Senior Scientist, Grünenthal)

In a Virtual World, Where Are the Walls of the House? The New Outsourcing.

A Combination of Standard and Innovative Technologies for Translational ADME-Tox Science

Cyprotex 4th European Drug Discovery Workshop 2010: Special considerations of compound in vitro profiling during fast progression to clinical phases by Dr. Constance Höfer (Founder and Chief Scientist, DMPKORE)

Cyprotex 5th NA Drug Discovery Workshop 2010: The role of hepatic and renal uptake transporters in drug discovery and development by Dr. Sonia de Morais (Director of DMPK, Abbott Labs)

Cyprotex 5th NA Drug Discovery Workshop 2010: Targeted solutions to DMPK problems: avoiding unnecessary screening by Dr. Bernard Murray (Senior Research Scientist I, Gilead)

Cyprotex 5th NA Drug Discovery Workshop 2010: Metabolite identification in drug discovery by Dr. Ron Aoyama (Senior Scientist I-DMPK, Exelixis)

Cyprotex 5th NA Drug Discovery Workshop 2010: Research strategies in LG and LO: combining in vitro and in vivo ADME approaches by Dr. Norman Huebert (Team Leader & Research Fellow ADME, Johnson & Johnson)

Cyprotex 5th NA Drug Discovery Workshop 2010: Drug metabolism in gut microbiota: a case study involving a pyridine N-oxide compound by Dr. Shichang Miao & Tim Stratton (Director DMPK, ChemoCentryx & Scientist, ChemoCentryx

Cyprotex 5th NA Drug Discovery Workshop 2010: Comparison of strategies for assessing metabolic stability in vitro

Cyprotex 5th NA Drug Discovery Workshop 2010: P-gp based drug interactions at the blood-brain barrier: Fact or fantasy? by Peng Hsiao (Research Assistant, University of Washington)

Cyprotex 4th NA Drug Discovery Workshop 2009: Identification of reactive metabolites in early drug discovery

LRIG New Jersey 2008 presentation: Improving candidate quality through the prediction of clinical outcome

Cyprotex drug discovery workshop 2007 presentation: Identification of reactive metabolites in early drug discovery

Cyprotex drug discovery workshop 2007 presentation: Screening for P-gp inhibition in vitro: Assays and implications

Toxicology

Enhancing Seizure Prediction using MEA Models - SPS2021

Development of a High Throughput High Content Imaging-based Mitobiogenesis Assay-SOT2019

Prediction of Liabilities with Chronic Drug Treatment in iPSC-Derived Cardiomyocytes using an MEA Platform-SOT2019

Evaluation of Pilocarpine in Multiple Neuronal Cell Types Using Microelectrode Array - Oral presentation SPS 2018

Uncertainty and Variability in High Throughput Toxicokinetics for Risk Prioritization

The development and characterisation of 3D neuronal microtissues for safety testing

DMG 2017 In vitro 3D toxicology models

Development of 3D cardiac and hepatic microtissue models for the improved prediction of clinical cardio- and hepatotoxicity

A Novel in vitro Neurotoxicity Assay that Accurately Predicts Seizurogenic Compounds

Utilization of In Vitro Mechanistic and 3D Models to Improve the Prediction of Hepatotoxicity and Cardiotoxicity

A novel in vitro neurotoxicity assay that accurately predicts seizurogenic compounds

eCiphrCardio and eCiphrNeuro: Assessing Toxicity using a Microelectrode Array

2012 DMDG Open Meeting:Comparison of in vitro approaches using high content screening to investigate metabolism-mediated toxicity

Advances in Mechanistic High Content Toxicology Webinar

The Role of In Vitro Assays in Determining Metabolite-Mediated Toxicity

New Screening Approach for Assessing Neuronal Activity and Neurotoxicity

eCiphrCardio - Assessing Cardiotoxicity through field potential using a Microelectrode Array

In silico

Cyprotex 4th European Drug Discovery Workshop 2010: Physiologically based pharmacokinetic/ pharmacodynamic modelling for lead optimisation of CNS-Active therapeutics by Dr. Simon Thomas (Head of Scientific Computing, Cyprotex Discovery)

Cyprotex 5th NA Drug Discovery Workshop 2010: PBPK modelling for the intergration of ADME data during drug discovery

Cyprotex 4th NA Drug Discovery Workshop 2009: Physiologically Based Pharmacokinetics Modelling

Make enquiry

Related pages

Close

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683

Email:
enquiries@cyprotex.com

or fill out the form below:

Close

Close

Download file

Close